The CMS issued final regulations that will make Medicare Part D claims data available to the Food and Drug Administration, other government agencies and academic researchers for patient-safety initiatives.
The FDA specifically plans to use Medicares prescription drug data to pilot test its Sentinel Initiative, a new electronic system that will enable the agency to query a vast array of health information databases to more effectively identify post-market adverse events.
With the Sentinel system we will no longer have to wait years to see how a drug or medical device is affecting millions of people, said FDA Commissioner Andrew von Eschenbach, who joined HHS Secretary Mike Leavitt and acting CMS Administrator Kerry Weems at a news conference to announce the health IT initiatives. Instead, the FDA will have the ability to monitor a products performance in real time, he said.
Linking claims data from 25 million beneficiaries that have prescription drug coverage to other Medicare claims information, including diagnoses, medical treatments, hospitalizations, and physician services will provide the FDA and other agencies and researchers with a new tool to investigate potential drug safety problems and questions about health outcomes, according to a statement from HHS.
Medicare beneficiaries with their high usage of medications and chronic health conditions, makes them the group most likely to benefit from the FDA Sentinel Initiative, Weems said.
In the second phase of this initiative, HHS hopes to expand this work to patients with private sector insurance, a CMS spokesman said. -- by Jennifer Lubell
What do you think? Post a comment on this article and share your opinion with other readers. Submit your comments to Modern Healthcare Online at [email protected]. Please be sure to include your hometown and state, along with your organization and title.